reports
Midland States Bancorp, Inc. Announces Planned Retirement of Jeffrey S...
Midland States Bancorp, Inc. Announces Planned Retirement of Jeffrey S. Mefford EFFINGHAM, Ill., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Midland States Bancorp, Inc. (Nasdaq: MSBI) (the “Company”), announced today Jeffrey S. Mefford will retire from his role as President of its wholly-owned subsidiary Midland States Bank (the “Bank”) and as Executive Vice President of the Company on June 30, 2026. Mefford has served as President of the Bank for seven years and has been employed with the Bank for 22 years. “Jeff has played a key role in our growth over many years, particularly in strengthening ...
Midland States Bancorp, Inc. Announces Authorization of New $25 Millio...
Midland States Bancorp, Inc. Announces Authorization of New $25 Million Stock Repurchase Program EFFINGHAM, Ill., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Midland States Bancorp, Inc. (NASDAQ: MSBI) announced today that its Board of Directors has approved a new stock repurchase program that authorizes the Company to repurchase up to $25 million of its common stock. The new stock repurchase program will become effective on November 3, 2025 and expires on November 2, 2026. The Company’s most recent stock repurchase program expired on December 31, 2024. Jeffrey G. Ludwig, President and Chief Execu...
Midland States Bancorp, Inc. Announces Common Stock and Preferred Stoc...
Midland States Bancorp, Inc. Announces Common Stock and Preferred Stock Dividends EFFINGHAM, Ill., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Midland States Bancorp, Inc. (NASDAQ: MSBI) announced today that its Board of Directors declared a quarterly cash dividend of $0.32 per share of its common stock. The dividend is payable on November 21, 2025 to all shareholders of record as of the close of business on November 14, 2025. The Board of Directors also declared a cash dividend of $0.4844 per depository share on its 7.75% Fixed-Rate Reset Non-Cumulative Perpetual Preferred Stock, Series A. The di...
Midland States Bancorp, Inc. Announces 2025 Third Quarter Results
Midland States Bancorp, Inc. Announces 2025 Third Quarter Results EFFINGHAM, Ill., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Midland States Bancorp, Inc. (Nasdaq: MSBI) (the “Company”) today reported net income available to common shareholders of $5.3 million, or $0.24 per diluted share, for the third quarter of 2025, compared to net income available to common shareholders of $9.8 million, or $0.44 per diluted share, for the second quarter of 2025. This also compares to net income of $18.2 million, or $0.83 per diluted share, for the third quarter of 2024. 2025 Third Quarter Results Net incom...
Midland States Bancorp, Inc. to Announce Third Quarter 2025 Financial ...
Midland States Bancorp, Inc. to Announce Third Quarter 2025 Financial Results on Thursday, October 30 EFFINGHAM, Ill., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Midland States Bancorp, Inc. (NASDAQ: MSBI) announced today that it will issue its third quarter 2025 financial results after market close on Thursday, October 30, 2025. Along with the press release announcing the financial results, the Company will publish an investor presentation that will be available on the page of its investor relations website. About Midland States Bancorp, Inc. Midland States Bancorp, Inc. is a community-based f...
89bio, Inc. Announces Agreement to be Acquired by Roche
89bio, Inc. Announces Agreement to be Acquired by Roche – 89bio stockholders to receive up to $20.50 per share in cash, comprised of $14.50 per share in cash at closing and a non-tradeable contingent value right (CVR) to receive up to an aggregate of $6.00 per share in cash; transaction represents total equity value of up to approximately $3.5 billion – – Transaction reflects pegozafermin’s potential best-in-disease profile for the treatment of moderate to severe metabolic dysfunction-associated steatohepatitis (MASH) – – 89bio to join the Roche Group as part of Roche’s Pharmaceutical...
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN FRANCISCO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 64,750 shares of the Company’s common stock to three new employees (the “Inducement ...
89bio to Participate in Upcoming Investor Conferences
89bio to Participate in Upcoming Investor Conferences SAN FRANCISCO, Aug. 28, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Company’s management will participate in the following investor conferences during the month of September: Citi’s 2025 Biopharma Back to School ConferenceFormat:Fireside ChatDate:Wednesday, September 3, 2025Time:11:15 AM EDT Cantor Global Healthcare Conference 2025...
Midland States Bancorp, Inc. receives expected notification of deficie...
Midland States Bancorp, Inc. receives expected notification of deficiency from Nasdaq related to delayed filing of Quarterly Report on Form 10-Q EFFINGHAM, Ill., Aug. 22, 2025 (GLOBE NEWSWIRE) -- Midland States Bancorp, Inc. (NASDAQ: MSBI) (the “Company”) today announced that it received an expected deficiency notification letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) on August 19, 2025 (the “Notice”). The Notice indicated that the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Listing Rule”) as a result of its failure to t...
89bio Reports Second Quarter 2025 Financial Results and Corporate Upda...
89bio Reports Second Quarter 2025 Financial Results and Corporate Updates – ENLIGHTEN-Fibrosis and ENLIGHTEN-Cirrhosis Phase 3 topline histology data expected in 1H 2027 and in 2028, respectively; each trial designed to support accelerated approval to treat patients with metabolic dysfunction-associated steatohepatitis (MASH) – – ENTRUST Phase 3 topline data in severe hypertriglyceridemia (SHTG) expected in 1Q 2026 – – Cash, cash equivalents, and marketable securities totaled $561.2 million as of June 30, 2025 – SAN FRANCISCO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq...
Midland States Bancorp, Inc. Increases Common Stock Cash Dividend to ...
Midland States Bancorp, Inc. Increases Common Stock Cash Dividend to $0.32 Per Share and Declares Preferred Stock Dividend EFFINGHAM, Ill., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Midland States Bancorp, Inc. (NASDAQ: MSBI) announced today that its Board of Directors declared a quarterly cash dividend of $0.32 per share of its common stock, an increase of 3.2% from the previous quarterly cash dividend of $0.31 per share. The dividend is payable on August 22, 2025 to all shareholders of record as of the close of business on August 15, 2025. The Board of Directors also declared a cash dividend ...
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN FRANCISCO, Aug. 04, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 267,000 shares of the Company’s common stock to three new employees (the “Inducement ...
Midland States Bancorp, Inc. Announces 2025 Second Quarter Results
Midland States Bancorp, Inc. Announces 2025 Second Quarter Results EFFINGHAM, Ill., July 24, 2025 (GLOBE NEWSWIRE) -- Midland States Bancorp, Inc. (Nasdaq: MSBI) (the “Company”) today reported net income available to common shareholders of $9.8 million, or $0.44 per diluted share, for the second quarter of 2025, compared to net income available to common shareholders of $23.5 million, or $1.06 per diluted share, for the second quarter of 2024. This also compares to a net loss of $143.2 million, or $6.58 per diluted share, for the first quarter of 2025, which included impairment of goodwi...
Midland States Bancorp, Inc. to Announce Second Quarter 2025 Financial...
Midland States Bancorp, Inc. to Announce Second Quarter 2025 Financial Results on Thursday, July 24 EFFINGHAM, Ill., July 10, 2025 (GLOBE NEWSWIRE) -- Midland States Bancorp, Inc. (NASDAQ: MSBI) announced today that it will issue its second quarter 2025 financial results after market close on Thursday, July 24, 2025. Along with the press release announcing the financial results, the Company will publish an investor presentation that will be available on the page of its investor relations website. About Midland States Bancorp, Inc. Midland States Bancorp, Inc. is a community-based finan...
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN FRANCISCO, July 09, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 32,350 shares of the Company’s common stock to two new employees (the “Inducement Gra...
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN FRANCISCO, June 06, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 61,100 shares of the Company’s common stock to three new employees (the “Inducement G...
89bio to Participate in Goldman Sachs 46th Annual Global Healthcare Co...
89bio to Participate in Goldman Sachs 46th Annual Global Healthcare Conference SAN FRANCISCO, June 04, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Company’s Management will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference on Wednesday, June 11, 2025 at 11:20 AM EDT and participate in one-on-one investor meetings. T...
Midland States Bancorp, Inc. receives expected notification of deficie...
Midland States Bancorp, Inc. receives expected notification of deficiency from Nasdaq related to delayed filing of Quarterly Report on Form 10-Q EFFINGHAM, Ill., May 23, 2025 (GLOBE NEWSWIRE) -- Midland States Bancorp, Inc. (NASDAQ: MSBI) (the “Company”) today announced that it received an expected deficiency notification letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) on May 19, 2025 (the “Notice”). The Notice indicated that the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Listing Rule”) as a result of its failure to timel...
Texas Pacific Land Corp: 1 director
A director at Texas Pacific Land Corp bought 10 shares at 1,399.380USD and the significance rating of the trade was 50/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two year...
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN FRANCISCO, May 09, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 183,885 shares of the Company’s common stock to seven new employees (the “Inducement G...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.